

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/993,045	11/13/2001	Timothy R. Brazelton	286002021300	8147
25226 7:	590 05/05/2003			
MORRISON & FOERSTER LLP			EXAMINER	
755 PAGE MILL RD PALO ALTO, CA 94304-1018			LI, QIAN J	
PALO ALTO,	CA 94304-1018			
			ART UNIT	PAPER NUMBER
		•	1632	<u> </u>
			DATE MAILED: 05/05/2003	6

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)		
Office Action Summary		09/993,045	BRAZELTON ET AL.		
		Examiner	Art Unit		
		Q. Janice Li	1632		
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status					
1)⊠	Responsive to communication(s) filed on 26 M	<u>//ay 2002</u> .			
2a)□	This action is <b>FINAL</b> . 2b)⊠ Thi	is action is non-final.			
3)□					
Dispositi	on of Claims				
4)🖂	Claim(s) $\underline{1-34}$ is/are pending in the application				
4a) Of the above claim(s) is/are withdrawn from consideration.					
5)□	Claim(s) is/are allowed.				
6)□	Claim(s) is/are rejected.				
7)	Claim(s) is/are objected to.				
8)🖂	Claim(s) 1-34 are subject to restriction and/or e	election requirement.			
Applicati	on Papers				
9)[	The specification is objected to by the Examiner	<b>.</b>			
10)	Γhe drawing(s) filed on is/are: a)□ accep	ted or b)⊡ objected to by the Exa	miner.		
	Applicant may not request that any objection to the	•	` '		
11) 🔲 -	The proposed drawing correction filed on	is: a)☐ approved b)☐ disappro	ved by the Examiner.		
If approved, corrected drawings are required in reply to this Office action.					
12)☐ The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) ☐ All b) ☐ Some * c) ☐ None of:					
1. Certified copies of the priority documents have been received.					
	2. Certified copies of the priority documents have been received in Application No				
<ul> <li>Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>					
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
a) ☐ The translation of the foreign language provisional application has been received.  15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.					
Attachment(s)					
1)  Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152)		
<u> </u>					

Art Unit: 1632

## **DETAILED ACTION**

Claims 1-34 are pending in the application.

## Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S. C. 121:
  - Claims 1-33 are drawn to a method for treating a neuronal disorder comprising administering bone marrow-derived cells to an individual in need thereof.
     Classified in class 435, subclass 325, and 455.
  - II. Claim 34 is drawn to a method for treating a neuronal deficiency comprising administering a bone marrow cell mobilization therapy to an individual in need thereof. Classification is to be determined depending on the nature of the therapy.
- The inventions are distinct, each from the other because of the following reasons.
   Inventions II and I are independent and distinct inventions. Inventions are

distinct if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the invention group I administering bone marrow-derived cells, whereas group II mobilizing the cells in the bone marrow. The different methods have different method steps, different modes of operation, and have distinct technical considerations.

Art Unit: 1632

The differences of the Inventions are further underscored by their divergent classification and independent search criteria.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter and different search criteria, it would impose an undue burden to the Office if all the groups are examined together, thus, restriction for examination purposes as indicated is proper.

- 3. This application contains claims directed to the following patentably distinct species of the claimed invention:
- I. Both of groups II and I are drawn to methods of treating various types of neuronal deficiency and memory function disorders such as those listed in claim 2, and those summarized in pages 14-23 of the specification.
- II. Group I is drawn to using various types of bone marrow-derived cells, i.e. autologus, allogenic and xenogenic.
- III. Group I is drawn to using various neuronal factors in conjunction with the cells, such as those recited in claim 9.

Upon election of an invention for examination in this application, further election of a species is necessary. If invention group I is elected, the applicant is required to elect one component from each of the three species listed above, which forms a combination of species drawn to a method for treating a particular neuronal disease using a particular type of BM cells in conjunction with a particular neuronal factor.

Art Unit: 1632

S

Applicant is required under 35 U.S.C. 121 to elect a single disclosed (combination of) species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1-5, 7-21, 34 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Art Unit: 1632

Ú

4. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is advised that where a single claim encompasses more than one invention as defined above, upon election of an invention for examination, said claim will only be examined to the extent that it reads upon the elected invention.

- 5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Q. Janice Li whose telephone number is 703-308-7942. The examiner can normally be reached on 8:30 am 5 p.m., Monday through Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Deborah J. Reynolds can be reached on 703-305-4051. The fax numbers for the organization where this application or proceeding is assigned are 703-872-9306 for regular communications and 703-872-9307 for After Final communications.

Any inquiry of formal matters can be directed to the patent analyst, Dianiece Jacobs, whose telephone number is (703) 305-3388.

Art Unit: 1632

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235. The faxing of such papers must conform to the notice published in the Official Gazette 1096 OG 30 (November 15, 1989).

Q. Janice Li Examiner Art Unit 1632

QJL May 2, 2003